NCT07333118

A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate-to-Severe Refractory Autoimmune Diseases

• Status: Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 22 (estimated)
• Sponsor: Grit Biotechnology · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is a single-arm, open-label, dose-escalation and dose-expansion clinical trial designed to evaluate the safety, efficacy, and cellular metabolism kinetics of GT801 in the treatment of moderate-to-severe refractory autoimmune diseases.

Conditions

• Moderate to Severe Refractory Autoimmune Disease

Interventions

Type	Name	Description
BIOLOGICAL	GT801 Injection	GT801 Injection

Timeline

• Start date: 2025-11-07
• Primary completion: 2028-03-31
• Completion: 2028-03-31
• First posted: 2026-01-12
• Last updated: 2026-01-12

Locations

1 site across 1 country: China